Literature DB >> 18758832

Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients.

L Spicuzza1, C Sciuto, G Vitaliti, G Di Dio, S Leonardi, M La Rosa.   

Abstract

In patients with cystic fibrosis (CF), there is an increasing incidence of some uncommon respiratory pathogens, such as Burkholderia cepacia complex (Bcc), Stenotrophomonas maltophilia, and Achromobacter xylosoxidans. In order to evaluate the prevalence and the clinical impact of these pathogens, we retrospectively studied a total of 109 patients followed in our center from 1996 to 2006 and reviewed the results of 1,550 sputum samples. The isolation of Pseudomonas aeruginosa slightly decreased over the observed decade, whereas Staphylococcus aureus exhibited an irregular trend. Infection with Bcc reached a peak in 1998 and successively decreased to a stable 4%. S. maltophilia and A. xylosoxidans were the real emerging pathogens, since first isolation occurred in 2004; however, the percentage of infected patients remained low (7% and 3.2%, respectively) through the years. In conclusion, in our center for CF, the reduced prevalence of P. aeruginosa over the last decade has been associated with a concurrent reduction of infections by Bcc and, as compared to other centers in Italy, Europe, and the US, with a low incidence of emerging pathogens such as S. maltophilia and A. xylosoxidans.

Entities:  

Mesh:

Year:  2008        PMID: 18758832     DOI: 10.1007/s10096-008-0605-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status.

Authors:  A Agodi; E Mahenthiralingam; M Barchitta; V Gianninò; A Sciacca; S Stefani
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

2.  Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis.

Authors:  I Talmaciu; L Varlotta; J Mortensen; D V Schidlow
Journal:  Pediatr Pulmonol       Date:  2000-07

3.  Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.

Authors:  A M Jones; M E Dodd; J R W Govan; V Barcus; C J Doherty; J Morris; A K Webb
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

Review 4.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

5.  Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.

Authors:  Silvia Campana; Giovanni Taccetti; Novella Ravenni; Isabella Masi; Sandra Audino; Barbara Sisi; Teresa Repetto; Gerd Döring; Maurizio de Martino
Journal:  J Cyst Fibros       Date:  2004-08       Impact factor: 5.482

6.  The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.

Authors:  L Sun; R Z Jiang; S Steinbach; A Holmes; C Campanelli; J Forstner; U Sajjan; Y Tan; M Riley; R Goldstein
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

7.  Alcaligenes infection in cystic fibrosis.

Authors:  Kenneth Tan; Steven P Conway; Keith G Brownlee; Christine Etherington; Daniel G Peckham
Journal:  Pediatr Pulmonol       Date:  2002-08

8.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Authors:  J L Burns; J Emerson; J R Stapp; D L Yim; J Krzewinski; L Louden; B W Ramsey; C R Clausen
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

9.  Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.

Authors:  Gavin R Graff; Jane L Burns
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

10.  Microbiology of airway disease in a cohort of patients with cystic fibrosis.

Authors:  Antonietta Lambiase; Valeria Raia; Mariassunta Del Pezzo; Angela Sepe; Vincenzo Carnovale; Fabio Rossano
Journal:  BMC Infect Dis       Date:  2006-01-11       Impact factor: 3.090

View more
  27 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  Pamela McGhee; Catherine Clark; Kim Credito; Linda Beachel; Glenn A Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Stenotrophomonas maltophilia strains replicate and persist in the murine lung, but to significantly different degrees.

Authors:  Ruella Rouf; Sara M Karaba; Jenny Dao; Nicholas P Cianciotto
Journal:  Microbiology (Reading)       Date:  2011-05-05       Impact factor: 2.777

4.  Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis.

Authors:  Giovanni Di Bonaventura; Arianna Pompilio; Roberta Zappacosta; Francesca Petrucci; Ersilia Fiscarelli; Cosmo Rossi; Raffaele Piccolomini
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

Review 5.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

6.  Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations.

Authors:  María Carmen Turrientes; María Rosario Baquero; María Blanca Sánchez; Sylvia Valdezate; Esther Escudero; Gabrielle Berg; Rafael Cantón; Fernando Baquero; Juan Carlos Galán; José Luis Martínez
Journal:  Appl Environ Microbiol       Date:  2010-01-22       Impact factor: 4.792

Review 7.  Community-acquired Stenotrophomonas maltophilia infections: a systematic review.

Authors:  M E Falagas; A C Kastoris; E K Vouloumanou; G Dimopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-18       Impact factor: 3.267

8.  Overexpression of the Efflux Pumps SmeVWX and SmeDEF Is a Major Cause of Resistance to Co-trimoxazole in Stenotrophomonas maltophilia.

Authors:  María Blanca Sánchez; José Luis Martínez
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

9.  Epidemiology and outcomes of Stenotrophomonas maltophilia and Burkholderia cepacia infections among trauma patients of India: a five year experience.

Authors:  Nonika Rajkumari; Purva Mathur; Amit K Gupta; Kumkum Sharma; Mahesh C Misra
Journal:  J Infect Prev       Date:  2014-12-10

10.  Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis method.

Authors:  Hoang Vu-Thien; Katia Hormigos; Gaëlle Corbineau; Brigitte Fauroux; Harriet Corvol; Didier Moissenet; Gilles Vergnaud; Christine Pourcel
Journal:  BMC Microbiol       Date:  2010-01-27       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.